Loading
A phase 3 trial of Technetium Tc-99m sulfur colloid in Breast cancer, run by HTA Co., Ltd., completed.
Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer is a phase 3 interventional study registered as NCT07764653 by HTA Co., Ltd., with 213 participants recorded, started 2024-01-02 and reaching its primary completion in 2025-06-03. Interventions recorded: Technetium Tc 99m Sulfur Colloid Injection, Mitoxantrone Hydrochloride Injection for Tracing. Conditions recorded: Sentinel Nodes, Breast Cancer.
Linked to the drug Technetium Tc-99m sulfur colloid because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Technetium Tc-99m sulfur colloid, Breast cancer (all types) and the tag pipeline.
Shares Technetium Tc-99m sulfur colloid and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/